Evidence map›Paper›PMID 31065565›Full record

ArticleOpen forum infectious diseases2019

Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study.

Jessica R Galloway-Peña, Christine B Peterson, Farida Malik, Pranoti V Sahasrabhojane, Dimpy P Shah, Chelcy E Brumlow, Lily G Carlin, Roy F Chemaly, Jin Seon Im, Gabriela Rondon and 9 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Jessica R Galloway-PeñaDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Christine B PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
Farida MalikDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Pranoti V SahasrabhojaneDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Dimpy P ShahDepartment of Epidemiology and Biostatistics, Long School of Medicine and Mays Cancer Center, University of Texas Health Science Center at San Antonio.
Chelcy E BrumlowDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Lily G CarlinDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Roy F ChemalyDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Jin Seon ImDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston.
Gabriela RondonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston.
Edd FelixDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
Lucas VeillonDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston.
Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston.
Amin M AlousiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston.
Robert R JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston.
Dimitrios P KontoyiannisDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Elizabeth J ShpallDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
Samuel A ShelburneDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.
Pablo C OkhuysenDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston.ORCID 0000-0002-1596-3411
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at San Antonio · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
Identifying Risk Factors for Antibiotic Resistance via Integration of Epidemiology and MetagenomicsK01AI143881 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GALLOWAY-PENA, JESSICA RHEA · 2019 to 2023
$545k
NCI NIH HHS L30 CA209245NCI NIH HHS P30 CA016672NIAID NIH HHS K01 AI143881NIH HHS S10 OD012304
6 · The paper itself

Abstract

backgroundAccumulating evidence suggests that the intestinal microbiome may dramatically affect the outcomes of hematopoietic stem cell transplant (HSCT) recipients. Providing 16S ribosomal RNA based microbiome characterization in a clinically actionable time frame is currently problematic. Thus, determination of microbial metabolites as surrogates for microbiome composition could offer practical biomarkers.

methodsLongitudinal fecal specimens (n = 451) were collected from 44 patients before HSCT through 100 days after transplantation, as well as 1-time samples from healthy volunteers (n = 18) as controls. Microbiota composition was determined using 16S ribosomal RNA V4 sequencing. Fecal indole and butyrate levels were determined using liquid chromatography tandem mass spectrometry.

resultsAmong HSCT recipients, both fecal indole and butyrate levels correlated with the Shannon diversity index at baseline (

conclusionsLongitudinal analysis of fecal microbiome and metabolites after HSCT identified butyrate and indole as potential surrogate markers for microbial diversity and specific taxa. Further studies are needed to ascertain whether fecal metabolites can be used as biomarkers of acute iGVHD or bacteremia after HSCT.

Indexed as

butyrategraft-vs-host disease (GVHD)hematopoietic stem cell transplant (HSCT)indolemicrobiome

Identifiers

PMID31065565
PMCPMC6499899
OpenAlexW2933318385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.